clinical trial · NCT06740630
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline·phase3·recruiting·n = 1,840
ChickenpoxInvestigational varicella vaccine_Lot 1Investigational varicella vaccine_Lot 2Investigational varicella vaccine_Lot 3Marketed varicella vaccine_Lot 1Marketed varicella vaccine_Lot 2MMR vaccineHepatitis A vaccinePCV (pneumococcal conjugate vaccine) 13
brief summary
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.
started
Jan 10, 2025
primary completion
Dec 25, 2026
completion
May 13, 2027
last updated
Mar 7, 2025
official title
A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol